| Name | Title | Contact Details |
|---|
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.
Paragon Laboratories is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Maag Prescription is a Pocatello, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Launched in April 2020, Talkiatry provides accessible in-network psychiatric care. The technology-driven service is committed to providing the highest level of mental health care on an outpatient basis. Based in New York City, Talkiatry offers seamless telehealth as well as in-person care in thoughtfully-designed, upscale offices—all at affordable, in-network prices. Talkiatry accepts a wide-range of insurance and employs psychiatrists and psychiatric nurse practitioners curated from among the city`s finest healthcare providers.
Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.